

Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



British Mycological
Society promoting fungal science

journal homepage: www.elsevier.com/locate/fbr



Review

Fungal endophytes and bioprospecting

T. S. SURYANARAYANAN^{a,*}, N. THIRUNAVUKKARASU^b, M. B. GOVINDARAJULU^b,
F. SASSE^c, R. JANSEN^d, T. S. MURALI^{a,1}

^aVivekananda Institute of Tropical Mycology, RKM Vidyapith, RKM Vivekananda College, Chennai, India

^bPG & Research Department of Botany, RKM Vivekananda College, Chennai, India

^cHelmholtz Centre for Infection Research, Department of Chemical Biology, Braunschweig, Germany

^dHelmholtz Centre for Infection Research, RG Microbial Drugs, Braunschweig, Germany

ARTICLE INFO

Article history:

Received 29 July 2009

Accepted 29 July 2009

Keywords:

Bioprospecting

Drug discovery

Endophytes

Fungal metabolites

Mycotechnology

ABSTRACT

Horizontally transmitted fungal endophytes are an ecological group of fungi, mostly belonging to the Ascomycota, that reside in the aerial tissues and roots of plants without inducing any visual symptoms of their presence. These fungi appear to have a capacity to produce an array of secondary metabolites exhibiting a variety of biological activity. Although the ability of fungi to produce unique bioactive metabolites is well known, endophytes have not been exploited, perhaps because we are only beginning to understand their distribution and biology. This review emphasizes the need to routinely include endophytic fungi in the screening of organisms for bioactive metabolites and novel drugs; it also underscores the need to use information obtained concerning fungal secondary metabolite production from other groups of fungi for a targeted screening approach.

© 2009 The British Mycological Society. Published by Elsevier Ltd. All rights reserved.

1. Introduction

For several years, natural products have been used directly as drugs or have provided the basic chemical architecture for deriving such drugs. There are at least 200,000 natural metabolites with bioactive properties (Bérdy, 2005). For instance, about 52 % of the new chemicals introduced into the market worldwide between 1981 and 2002 were natural products or their derivatives (Chin *et al.*, 2006). Besides plants, microorganisms constitute a major source of natural products with desirable bioactive properties. More than 20,000 bioactive metabolites of microbial origin were known by the end of 2002 (Bérdy, 2005). Fungi are among the most important groups of eukaryotic organisms that are being

explored for metabolites for clinical applications. Existing drugs of fungal origin include β -lactam antibiotics, griseofulvin, cyclosporine A, taxol, ergot alkaloids, and lovastatin. More new natural products of varied chemical structures are continually being reported from fungi (Grabley and Sattler, 2003; Mitchell *et al.*, 2008; Stadler and Keller, 2008). The versatile synthetic capability of fungi reflects their heterotrophic and absorptive mode of nutrition and the ability to exploit a variety of substrates and habitats (Hyde, 2005; Suryanarayanan and Hawksworth, 2005). We know only about 7 % of the estimated 1.5 million species of fungi (Hawksworth, 2004), and only very few of these have been cultivated and screened for drug production. It is therefore logical to postulate that we have only discovered a small

* Corresponding author.

E-mail address: t_sury2002@yahoo.com (T.S. Suryanarayanan).

¹ Division of Biotechnology, Manipal Life Sciences Centre, Manipal, Karnataka, India

1749-4613/\$ – see front matter © 2009 The British Mycological Society. Published by Elsevier Ltd. All rights reserved.

doi:10.1016/j.fbr.2009.07.001